TP53 and osteosarcoma: Intriguingly, we have recently found for the first time that siRNA-mediated silencing of RUNX2 in p53-proficient human osteosarcoma U2OS cells augments their adriamycin (ADR)-sensitivity in a p53/TAp73-dependent manner [24, 25].